BioNTech SE (BNTX.xnas) is a biotechnology company developing and commercialising immunotherapies for cancer and other infectious diseases headquartered in Mainz, Germany. BioNTech develops pharmaceutical product candidates for advanced melanoma, prostate cancer, triple-negative breast cancer, ovarian cancer, cell lung cancer and neoantigen-specific immunotherapies, such as Autogene cevumeran. BioNTech along with Pfizer, developed the RNA vaccine BNT 162b2 to prevent COVID-19 infections, the first mRNA vaccine ever authorized and approved later in the United States, Canada, and Switzerland. BioNTech operates in Germany, San Diego, Cambridge, and Massachusetts, with 8 offices in 2 countries. The company employs 1323 people and has a market capitalisation of $73.41B (USD) as of December 2021. BioNTech stock (BNTX.xnas) is listed as American Depository Shares (ADS) on the NASDAQ Global Select Market. BioNTech plans to open its Asia headquarters in Singapore and a vaccine manufacturing plant with support from the Singapore Economic Development Board in 2023. BioNTech aim to produce hundreds of millions of doses of mRNA vaccines per year. In November 2021, BioNTech and Pfizer announced that a three-shot course of their COVID-19 vaccine was able to neutralise the new Omicron variant, and they could deliver an Omicron-based vaccine in March 2022 if needed.
BioNTech SE (BNTX)
Explore BioNTech SE (BNTX) share price news and trends to guide your investment strategy. Stay informed with FP Markets Ghana for smarter trading.